Corvus Pharmaceuticals Inc
General ticker "CRVS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $516.5M
Corvus Pharmaceuticals Inc follows the US Stock Market performance with the rate: 56.9%.
Estimated limits based on current volatility of 6.3%: low 4.34$, high 5.20$
Factors to consider:
- Current price 60.5% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.44$, 3.11$]
- 2024-12-30 to 2025-12-30 estimated range: [1.29$, 2.85$]
Financial Metrics affecting the CRVS estimates:
- Negative: Non-GAAP EPS, $ of -0.57 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -23.65 <= 2.35
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
- Positive: Inventory ratio change, % of -100 <= -1.03
- Positive: Interest expense per share, $ of 0.03 <= 0.14
Short-term CRVS quotes
Long-term CRVS plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
Operating Expenses | $38.63MM | $32.56MM | $23.41MM |
Operating Income | $-38.63MM | $-32.56MM | $-23.41MM |
Non-Operating Income | $-4.61MM | $-8.74MM | $-3.62MM |
Interest Expense | $0.01MM | $0.65MM | $1.58MM |
R&D Expense | $29.11MM | $24.47MM | $16.53MM |
Income(Loss) | $-43.24MM | $-41.31MM | $-27.03MM |
Taxes | $-5.04MM | $8.74MM | $0.00MM |
Profit(Loss) | $-38.20MM | $-50.05MM | $-27.03MM |
Stockholders Equity | $97.16MM | $56.12MM | $38.68MM |
Inventory | $0.67MM | $0.73MM | $0.00MM |
Assets | $109.45MM | $68.24MM | $45.55MM |
Operating Cash Flow | $-36.72MM | $-27.02MM | $-23.93MM |
Capital expenditure | $0.01MM | $0.27MM | $0.03MM |
Investing Cash Flow | $21.56MM | $-23.28MM | $15.54MM |
Financing Cash Flow | $62.16MM | $0.00MM | $7.86MM |
Earnings Per Share* | $-0.91 | $-1.08 | $-0.56 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.